Search

Your search keyword '"Shibolet, O."' showing total 4 results
Start Over Author "Shibolet, O." Language undetermined
4 results on '"Shibolet, O."'

2. Historical epidemiology of hepatitis C virus (HCV) in select countries - volume 2

Author

Saraswat, V, Norris, S, de Knegt, Rob, Sanchez Avila, JF, Sonderup, M, Zuckerman, E, Arkkila, P, Stedman, C, Acharya, S, Aho, I, Anand, AC, Andersson, MI, Arendt, V, Baatarkhuu, O, Barclay, K, Ben-Ari, Z, Bergin, C, Bessone, F, Blach, S, Blokhina, N, Brunton, CR, Choudhuri, G, Chulanov, V, Cisneros, L, Croes, EA (Esther), Dahgwahdorj, YA, Dalgard, O, Daruich, JR, Dashdorj, NR, Davaadorj, D, de Vree, M, Estes, C, Flisiak, R, Gadano, AC, Gane, E, Halota, W, Hatzakis, A, Henderson, C, Hoffmann, P, Hornell, J, Houlihan, D, Hrusovsky, S, Jarcuska, P, Kershenobich, D, Kostrzewska, K, Kristian, P, Leshno, M, Lurie, Y, Mahomed, A, Mamonova, N, Mendez-Sanchez, N, Mossong, J, Nurmukhametova, E, Nymadawa, P, Oltman, M, Oyunbileg, J, Oyunsuren, T, Papatheodoridis, G, Pimenov, N, Prabdial-Sing, N, Prins, M, Puri, P, Radke, S, Rakhmanova, A, Razavi, H, Razavi-Shearer, K, Reesink, HW, Ridruejo, E, Safadi, R, Sagalova, O, Sanduijav, R, Schreter, I, Seguin-Devaux, C, Shah, SR, Shestakova, I, Shevaldin, A, Shibolet, O, Sokolov, S, Souliotis, K, Spearman, CW, Staub, T, Strebkova, EA, Struck, D, Tomasiewicz, K, Undram, L, van der Meer, Adriaan, van Santen, D, Veldhuijzen, I, Villamil, FG, Willemse, S, Zuure, FR, Silva, MO, Sypsa, V, Gower, E, Amsterdam institute for Infection and Immunity, Amsterdam Public Health, Infectious diseases, Gastroenterology and Hepatology, Graduate School, Other departments, Gastroenterology & Hepatology, and Epidemiology

Subjects
Adult, Aged, 80 and over, Male, Adolescent, Hepatology, Infant, Newborn, Infant, Hepatitis C, Chronic, Middle Aged, Global Health, Antiviral Agents, Drug Utilization, Liver Transplantation, Young Adult, Infectious Diseases, SDG 3 - Good Health and Well-being, Child, Preschool, Virology, Prevalence, Humans, Female, Child, Aged
Abstract

Chronic hepatitis C virus (HCV) infection is a leading cause of liver related morbidity and mortality. In many countries, there is a lack of comprehensive epidemiological data that are crucial in implementing disease control measures as new treatment options become available. Published literature, unpublished data and expert consensus were used to determine key parameters, including prevalence, viremia, genotype and the number of patients diagnosed and treated. In this study of 15 countries, viremic prevalence ranged from 0.13% in the Netherlands to 2.91% in Russia. The largest viremic populations were in India (8 666 000 cases) and Russia (4 162 000 cases). In most countries, males had a higher rate of infections, likely due to higher rates of injection drug use (IDU). Estimates characterizing the infected population are critical to focus screening and treatment efforts as new therapeutic options become available.

Published
2015

3. Venous Thromboembolism during Pregnancy

Author

Brezis M, Shibolet O, and Schwaber Mj

Subjects
Pregnancy, medicine.medical_specialty, business.industry, Obstetrics, Medicine, General Medicine, business, medicine.disease, Venous thromboembolism
Published
1996

4. Effects of Tumor Necrosis Factor Antagonists in Patients With Primary Sclerosing Cholangitis

Author

Karima Ben Belkacem, Neta Gotlieb, Severine Vermeire, Christoph Schramm, Roger W. Chapman, Nicholas Fonseca Nogueira, Emma Nilsson, Henriette Ytting, Hanns-Ulrich Marschall, João Sabino, Sven Almer, Cyriel Y. Ponsioen, Geir Larsson, Kate D. Lynch, Gina Sado, Ellina Lytvyak, Douglas Thorburn, Bjørn Moum, Olivier Chazouillères, Oren Shibolet, Kim N. van Munster, Christian Rupp, Alessandra Zago, Fredrik Rorsman, Christopher L. Bowlus, K. K. Jørgensen, Cynthia Levy, Mette Vesterhus, Alessio Gerussi, Charlotte R H Hedin, Francesca Saffioti, Aldo J. Montano-Loza, Andrew Mason, Nora Cazzagon, Annika Bergquist, Nelson Ndegwa, Graduate School, AGEM - Amsterdam Gastroenterology Endocrinology Metabolism, Gastroenterology and Hepatology, Hedin, C, Sado, G, Ndegwa, N, Lytvyak, E, Mason, A, Montano-Loza, A, Gerussi, A, Saffioti, F, Thorburn, D, Nilsson, E, Larsson, G, Moum, B, van Munster, K, Ponsioen, C, Levy, C, Nogueira, N, Bowlus, C, Gotlieb, N, Shibolet, O, Lynch, K, Chapman, R, Rupp, C, Vesterhus, M, Jorgensen, K, Rorsman, F, Schramm, C, Sabino, J, Vermeire, S, Zago, A, Cazzagon, N, Marschall, H, Ytting, H, Ben Belkacem, K, Chazouilleres, O, Almer, S, and Bergquist, A

Subjects
musculoskeletal diseases, medicine.medical_specialty, Exacerbation, Cholangitis, Sclerosing, digestive system, Inflammatory bowel disease, Gastroenterology, Primary sclerosing cholangitis, Anti-Inflammatory, 03 medical and health sciences, 0302 clinical medicine, Hepatic, MED/12 - GASTROENTEROLOGIA, Interquartile range, Internal medicine, medicine, Adalimumab, Humans, Retrospective Studies, Hepatology, Tumor Necrosis Factor-alpha, business.industry, Inflammatory Bowel Diseases, medicine.disease, Infliximab, digestive system diseases, Intestine, Liver Transplantation, 030220 oncology & carcinogenesis, Tumor Necrosis Factor Inhibitors, 030211 gastroenterology & hepatology, Liver function, MED/09 - MEDICINA INTERNA, Calprotectin, business, medicine.drug
Abstract

Background & Aims: Few patients with primary sclerosing cholangitis (PSC) and inflammatory bowel diseases (IBDs) are exposed to tumor necrosis factor (TNF) antagonists because of the often mild symptoms of IBD. We assessed the effects of anti-TNF agents on liver function in patients with PSC and IBD, and their efficacy in treatment of IBD. Methods: We performed a retrospective analysis of 141 patients with PSC and IBD receiving treatment with anti-TNF agents (infliximab or adalimumab) at 20 sites (mostly tertiary-care centers) in Europe and North America. We collected data on the serum level of alkaline phosphatase (ALP). IBD response was defined as either endoscopic response or, if no endoscopic data were available, clinical response, as determined by the treating clinician or measurements of fecal calprotectin. Remission was defined more stringently as endoscopic mucosal healing. We used linear regression analysis to identify factors associated significantly with level of ALP during anti-TNF therapy. Results: Anti-TNF treatment produced a response of IBD in 48% of patients and remission of IBD in 23%. There was no difference in PSC symptom frequency before or after drug exposure. The most common reasons for anti-TNF discontinuation were primary nonresponse of IBD (17%) and side effects (18%). At 3 months, infliximab-treated patients had a median reduction in serum level of ALP of 4% (interquartile range, reduction of 25% to increase of 19%) compared with a median 15% reduction in ALP in adalimumab-treated patients (interquartile range, reduction of 29% to reduction of 4%; P =.035). Factors associated with lower ALP were normal ALP at baseline (P

Published
2020

Catalog

Books, media, physical & digital resources
See catalog results